the presentation of superantigens on MHC class II molecules, further modifying the circulating TCR HLA molecules have been suspected to play a role in repertoire. the pathogenesis of autoimmune disease since Brewerton
Despite a quarter of a century of investigation, mechet al. [1] recognized that HLA-B27 was associated with anisms of HLA involvement in autoimmune disease the rheumatic disease ankylosing spondylitis in 1973.
remain speculative. This is largely due to the difficulty This was followed by the description of associations of isolating the effect of a particular HLA molecule on between several class II MHC molecules and autothe disease studied. This problem has emerged in epiimmune diseases, including rheumatoid arthritis ( RA), demiological, genetic and immunological approaches to insulin-dependent diabetes (IDDM ) and multiple sclerthe study of these diseases.
osis (reviewed by Nepom and Ehrlich [2]). While this review focuses primarily on the association of HLA with
HLA is only one piece of the puzzle autoimmune disease, there is good evidence that HLA molecules also influence host defence against foreign HLA-associated autoimmune diseases are complex, arising as a result of the interaction of environmental pathogens [3, 4] , allergic responses and anti-tumour immunity [5] .
influences with a polygenic background of susceptibility. In some cases, HLA appears to exert a large influence A variety of hypotheses have been advanced, based on current understanding of the biology of HLA on the susceptibility to disease and in other diseases it is a relatively small component. molecules, to explain the HLA association with disease [6 ] . Crystallographic studies have demonstrated that
Neighbours tend to travel together MHC molecules bind peptide fragments in their binding cleft and present them to specific T-cell receptors ( TCRs)
The HLA complex encodes multiple HLA molecules [7] [8] [9] ; in general, class I MHC molecules present and a number of other immunologically active molecules intracellular peptides to CD8+ T cells, while class II [10] . Loci in close proximity exhibit linkage disequilibmolecules present peptides from extracellular proteins rium and HLA-DR and -DQ alleles, for example, are to CD4+ T cells. The remarkable polymorphism of usually inherited together. The demonstration of an MHC molecules dictates the specificity of peptide bindassociation between a disease and a particular locus ing and, in turn, influences the processes of thymic may reflect an effect of either the locus studied, an selection and peripheral T-cell activation. The most adjacent genetic locus or a combination. popular hypothesis for HLA association with disease is HLA functions in concert with the rest of the that certain HLA molecules present a 'pathogenic' pepimmunological orchestra tide or peptides, and thereby elicit a deleterious immune response from specific T cells. Alternatively, disease susThe influence of a particular HLA molecule on immune ceptibility could be determined by variations in TCR responses will be modified by the 'landscape' of the repertoire. For example, during thymic selection, certain other HLA molecules among which it is expressed. Each HLA molecules (or HLA-derived peptides presented by HLA molecule expressed modifies the TCR repertoire a second HLA molecule) may fail to delete potentially selected in the thymus and, in the periphery, may compete with other HLA molecules for peptide presentation. In addition, fragments of HLA molecules are in antigen processing, antigen recognition signalling and DRB loci may exhibit subtle regulatory differences and promoter polymorphisms may result in allelic differences effector functions. For example, variations in degradative enzymes, proteasome components, the TCR reperin expression [14, 15] . Despite these complexities, it has proved possible to establish HLA transgenic lines by toire, the signalling cascade or other co-stimulatory receptors, such as adhesion molecules, may all influence introducing HLA genes into mice under the control of their native human promoter. The tissue-specific expresthe immunogenicity of an epitope presented by a particular HLA molecule.
sion of the transgenes has been variable. However, in some models, the HLA molecules produced are funcIn addition, any study of human disease is hindered by the genetic variation between individuals and the tional [16] [17] [18] . An alternative approach is to introduce the HLA transgene under the control of a murine MHC obvious ethical constraints on immunizing individuals and analysing immune responses. Advances in molecular class II promoter. There are subtle differences between mice and humans in the expression of MHC class II biology have provided a number of new technologies, including the development of HLA transgenic mice, molecules, and the introduction of an HLA gene under the control of a murine promoter ensures more 'physiowith which to circumvent many of these problems. This enables the isolation, in vivo, of individual MHC logical' patterns of expression in the mouse. The I-Ea promoter has been used to make HLA-DR4 transgenic molecules in order to assess their role in the regulation of immune responses and, ultimately, the development mice [19] . The regulation of the transgenic HLA-DR appeared to be physiological, both in the thymus and and resolution of disease.
the periphery (including the absence of MHC class II molecules on activated murine T cells), and the molecule HLA transgenic mice: isolating the suspect was capable of functioning as a restriction element.
Even an optimal promoter does not guarantee physio-A panel of HLA transgenic lines provides a method for investigating the influence of individual HLA molecules logical expression in transgenic models. The level and pattern of expression may also be influenced by the on a number of immunological processes, including the following:
copy number and integration site of the transgene, and by the ability to associate with critical murine molecules $ Thymic selection of the TCR repertoire.
(e.g. invariant chain and H-2M for class II molecules, $ The determination of immunodominant epitopes and b2m for class I molecules). The MHC class II within a complex antigen.
overexpression syndrome, described in I-Ab transgenic $ The quality of the effector immune response (e.g. mice, is often related to integration of over 50 copies of cytokine profile) following an antigenic challenge.
the transgene. It manifests as inflammatory disease with $ The influence of individual HLA molecules on the low levels of cell surface MHC class II molecules, expression of murine models of human diseases.
progressive B-cell deficiency and abnormal extramedullary granulopoiesis with eosinophilia [20] [21] [22] . This The process of generating a meaningful HLA transgenic model in which to study 'humanized' immune phenotype can easily be mistaken for an HLA-related model of human inflammatory disease, whereas it responses is not trivial and extrapolating from murine to human disease poses an additional series of problems.
appears to be a non-specific effect resulting from the overexpression of any MHC class II allele. OverThe major issues can be summarized as follows:
expression of MHC class I molecules can also be associ-1. Does the HLA transgene produce a physiological ated with an inflammatory phenotype, as observed in pattern of HLA expression?
the high-copy-number HLA-B27 mice [23] , but it is 2. Does the human MHC molecule interact normally unclear how this relates to the pathogenesis of HLAwith murine components of the antigen-processing B27-associated diseases in humans. The stoichiometry and recognition pathways? of transgenic products (class II a and b chains) may 3. Does the presence of murine MHC molecules interalso influence expression and can be optimized by introfere with the study of human MHC molecules? ducing the transgenes in tandem, within a single con-4. In murine models of autoimmune disease, how closely struct [19] . Given these various considerations, it is do murine autoantigens resemble their human counnecessary to generate several founder lines, in order to terparts, both structurally and functionally?
obtain one with a physiological pattern of HLA expression. Each of these will be discussed, along with strategies used by us and by others to address these problems.
Does the human MHC molecule interact normally with murine components of the antigen-processing and Does the HLA transgene produce a physiological pattern of HLA expression? recognition pathways?
In general, it appears that trans-species interaction of The promoter regions of HLA class I and II genes determine the temporal pattern and tissue specificity of HLA molecules with murine cellular and immunological machinery is sufficient to allow the transgenic molecules expression, as well as the modulation of expression during inflammation (reviewed in Ting and Baldwin [12] to function as restriction elements, at least under some circumstances. Both HLA-DRa transgenic [24] and sevand Mach et al. [13] ). In addition to differences in regulation between classes of HLA genes, the DRA and eral DRa/DRb or DRa/DQb double transgenic mice exhibit reconstitution of HLA-restricted T-cell function although certain class I heavy chains, such as HLA-B27, can be expressed in the absence of b2m. These [16, 18, 19, [25] [26] [27] [28] .
Although transgenic HLA molecules can function in animals were developmentally normal, but lacked the CD8+CD4− T-cell compartment [40] . MHC class mice, it is possible that the nature of T cells activated by a given MHC/peptide stimulus may be different in II-deficient mice (I-Ab°) have been generated in the 129 cell line, which carries a mutation in the I-Ea gene HLA transgenic mice, compared with human subjects. T-cell activation is determined by the avidity of MHC/ promoter, preventing expression of the I-Eab heterodimer. Expression of the remaining class II molecule, peptide/TCR interaction, which is influenced by the quality of co-receptor binding. For example, CD4, I-A, was abolished by targeted disruption of the I-Ab gene [41] . The I-Ab°mice have very few CD4+ lymphoexpressed on T cells, stabilizes the interaction of TCR with peptide/class II MHC by binding to the membranecytes in the periphery and are unable to respond to T-cell-dependent antigens. Introduction of an HLA-DR proximal domain of both MHC class II b chains (a2 transgene on the I-Ab°background partially restores and b2 domains) and interacts with the src-family related the selection and function of CD4+ T cells ( Table 1) . tyrosine kinase, p56lck, intracellularly [29, 30] . CD8
The size of the CD4+ compartment approaches that in performs a similar function for peptide/MHC class I wild-type mice in murine models which are homozygous interactions with TCR with binding sites on the a2 and for both HLA-DR4 and appropriately regulated human b3 domains of the MHC class I molecule [31] . Although CD4 transgenes on a murine class II-deficient backmurine CD4 and CD8 appear to perform adequately as ground [33] . In mice of this genotype, the avidity of HLA molecule co-receptors in some systems [16, 18] , TCR interaction with the HLA-DR/peptide should there are other examples where HLA-restricted immune reflect most closely that observed in man and therefore responses have been rescued or augmented by the introprovide the best model of HLA-DR-restricted immune duction of transgenic human CD4 [32, 33] or human responses. CD8 [34] . The interaction of transgenic HLA molecules
The formation of a trans-species heterodimer is a with CD4 or CD8 co-receptors can be optimized by the potential confounding factor in HLA-DR transgenic, introduction of an additional transgene encoding either murine class II-deficient mice, since the human DRa human CD4 or human CD8. An early model introduced chain can pair with the murine I-Eb. As a control, we the human CD4 transgene under the control of the have made a separate DRA*0101 transgenic line on the murine CD3d promoter, resulting in human CD4 I-Ab°background, in which the DRa/I-Eb heterodimer molecule expression on all CD3+ cells, both CD4+ is the only class II molecule expressed. These mice are and CD8+ subsets, and low-level expression on B cells capable of selecting a functional CD4+ T-cell compart- [19] . Another approach has been to generate chimeric ment. However, when both DRA1 and DRB1 are intro-MHC molecules, in which the peptide-binding domains duced as transgenes, the formation of the trans-species of the molecule were derived from HLA molecules, heterodimer DRa/I-Eb becomes inefficient and only while the co-receptor binding site on the membrane-~5 % of antigen-specific T-cell hybridomas raised in proximal b chain was of murine origin [35] [36] [37] . A the HLA-DR4 transgenic mice are restricted by modified HLA-DRB1*0401 transgenic line has also been DRa/I-Eb [28] . developed, in which residues 110 and 139 of the DRb chain have been altered to resemble murine I-Ab, in
In murine models of autoimmune disease, how closely do order to improve interaction with murine CD4 [38] .
murine autoantigens resemble their human counterparts, The characterization of the murine CD4 transcriptional both structurally and functionally? enhancer/silencer element by Littman and colleagues
If HLA molecules present 'pathogenic' peptides from [39] enabled us to develop a new panel of human CD4, autoantigens, then trans-species variations in the auto-HLA-DR transgenic mice, in which human CD4 is appropriately expressed on CD4+, but not CD8+, cells antigen may result in a different HLA-restricted response transgenes exhibit the normal frequency of CD4+ T cells in the periphery [33] . to the murine equivalent of a human autoantigen. The islet cell antigen, glutamic acid decarboxylase 65 Determination of immunodominant epitopes within a (GAD65), is an autoantigen recognized early in the complex antigen development of both human and murine IDDM.
The association of particular HLA molecules with susPublished sequences reveal 95% amino acid sequence ceptibility to disease may be the result of a pathogenic identity between mice and humans, and it can probably immune response to the presentation of certain peptides. serve as an autoantigen on the relevant transgenic HLA If this model is correct, then it is important to identify class II molecules expressed in the mouse [42] . In the autoantigens involved in pathogenesis and to define contrast, the synovial autoantigen human cartilage the T-cell epitopes presented by individual HLA glycoprotein-39 (HCgp-39) is only 74% identical with molecules, which are associated with either disease susthe murine equivalent BRP-39 [43, 44] . The evaluation ceptibility or resistance. of its role in murine models of inflammatory arthritis HCgp-39 is a synovial autoantigen, which is not will probably necessitate the expression of human proconstitutively expressed, but which is secreted by chondtein (HCgp-39) as a transgene, in the relevant model. rocytes and synoviocytes during synovial inflammation. Concerns about the equivalence of human and murine Peripheral blood T cells from >50% patients with RA, disease pertain to all HLA transgenic murine models of and from HLA-DR-matched controls, respond spontanautoimmune, allergic or infectious disease. In the noneously to certain peptides from HCgp-39, which bear a obese diabetic (NOD) mouse model [45] and the DR*0401 motif [28, 51] . It is unclear whether HCgp-39 NZB/NZW murine model of systemic lupus erythis directly involved in the pathogenesis of disease, but ematosus [46 ] , disease occurs spontaneously, as in the its expression in the inflamed joint and its autoantigenichuman patient. However, other models, including the ity make it an attractive candidate for peptide-mediated collagen-induced arthritis (CIA) model [47] and the immunotherapy. HLA-DR4 transgenic mice have murine model of demyelinating disease, experimental been used to map the T-cell epitopes of HCgp-39 allergic encephalitis [48] , require the introduction of an in the context of the RA-associated HLA-DR4 allele, antigenic trigger. All autoimmune diseases are multifac-DR*0401 and the closely related disease-neutral/resisttorial and develop from an interplay of environmental ant allele DR*0402 [28] . Mice transgenic for HLA-DR4 influences on a background of polygenic susceptibility.
(either DR*0401 or DR*0402) and human CD4, but However, the genetic loci involved in humans are frelacking murine class II molecules (I-Ab°), were immunquently different to those implicated in the murine ized with HCgp-39 emulsified in incomplete Freund's model, as has been demonstrated through mapping the adjuvant. A panel of T-cell hybridomas was raised to susceptibility loci for IDDM in humans and NOD mice provide a 'snapshot' of the primary TCR repertoire [49, 50] . At best, murine models can be expected to responding to HCgp-39 in the context of HLA-DR*0401 reproduce selected features of human disease. However, or -DR*0402. The specificity of the T-cell hybridomas a human disease susceptibility gene, expressed in mice, was tested using HLA-DR4 positive antigen-presenting may have no demonstrable effect on the murine model cells (APC ), presenting whole HCgp-39, then pools of of disease. This may occur either because the pathooverlapping 16-mer peptides, which spanned the genesis of the disease is different in humans and mice, HCgp-39 molecule, by individual peptides from a stimuor because the mouse lacks the 'supporting' susceptibility latory pool and, finally, truncated variants of an indigenes, such as the critical human autoantigen(s) or vidual stimulatory peptide. This study revealed three the ability to produce a prominent interferon gamma immunodominant epitopes in the context of DR*0401 (IFN-c) response following antigen challenge.
(100-115, 262-277, 322-337) and two entirely distinct epitopes in the context of DR*0402 (22-37, 298-313) ( Table 2 ). All could also be presented by human APC
Compiling the evidence expressing the appropriate HLA-DR4 molecule, and each of the DR*0401 epitopes has been shown to elicit Thymic selection of the T-cell receptor repertoire secondary T-cell proliferative responses in some RA Selection of the CD4+ T-cell compartment is dependent patients. We are currently studying the kinetics of interon the presentation in the thymus of peptides on MHC action of these peptides with soluble recombinant class II molecules. Both positive and negative selection DR*0401 and DR*0402, and investigating the influence of T cells depend on the avidity of TCR interaction with of physiological pH variation and of HLA-DM on the peptide/MHC ligands. The I-Ab°murine lines, which stability of the complexes. express no murine class II MHC molecules, exhibit an Several autoantigens have been implicated in the almost complete failure to select CD4+ T cells [41] .
pathogenesis of IDDM, both in humans and in the The CD4+ compartment can be at least partially murine NOD model. These include preproinsulin and reconstituted by expressing transgenic human class II GAD65. HLA-DR*0401, hCD4, I-Ab°mice have been molecules, either HLA-DQ [26 ] or HLA-DR [33] . A used to map the T-cell epitopes of GAD65 presented by gene dosage effect is evident, since only the mice which the IDDM susceptibility allele, HLA-DR*0401 [33] .
Ten immunogenic epitopes were defined, of which six are homozygous for both HLA-DR4 and human CD4 example, HLA-A2 transgenic mice were used to assess the immunogenicity of substituted peptides from an HLA-A2-restricted HCV epitope. One variant, 8A, were recognized by multiple hybridomas. The immunoproved to be a more potent stimulator of cytotoxic dominant epitopes defined by this approach also elicit T-cell responses than the wild-type epitope [56 ] . secondary T-cell proliferative responses in patients Several autoimmune diseases are associated with with IDDM, further validating the approach. Two of apparent overproduction of certain cytokines. In both the peptides (271-286 and 551-570) defined in the IDDM and RA, for example, prominent Th1-like DR*0401 transgenic mice are also immunodominant in responses are evident in T cells from the islets of mice expressing either the strong susceptibility allele Langerhans or the inflamed synovium, respectively DR*0405 or the protective allele DR*0403 (S. Parry, [57] [58] [59] . In murine models of diabetes, disease can be unpublished).
accelerated by the adoptive transfer of autoaggressive The DR*0401, hCD4, I-Ab°mice have been similarly T-cell clones, which produce IFN-c [60] . HLA-transused to map the epitopes of insulin and its prohormones, genic mice can be used to investigate the cytokine proinsulin and preproinsulin [52] . These results demonprofiles elicited by the T-cell epitopes defined from strate that the prohormones, but not the mature insulin autoantigens. For example, following immunization of autoantigen, carry the immunodominant epitope in the DR*0401/hCD4/I-Ab°mice with HCgp-39, restimulacontext of DR*0401. The epitope, LALEGSLQK, was tion of the lymph node T cells in vitro with a pool of located at the junction of the C-peptide and A-chain, the DR*0401 immunodominant epitopes stimulated and it is proteolytically cleaved during maturation of prominent IFN-c and tumour necrosis factor alpha the insulin molecule. This epitope can be processed and ( TNF-a) responses. Lymph node T cells from similarly presented from prohormone by DR*0401-homozygous immunized DR*0402/hCD4/I-Ab°mice produced small Epstein-Barr virus-transformed human B-cell lines and amounts of IFN-c and no TNF-a [28] . Lymph node it is also recognized by T cells from the peripheral blood T cells from DR*0402 transgenic mice immunized with of HLA-DR4-positive patients with IDDM. the borrelial antigen, Osp A, elicited a substantial HLA transgenic mice have also been used to map IFN-c response, indicating that DR*0401 and DR*0402 T-cell epitopes from microbial antigens. For example, exert antigen-specific influences on the cytokine treatment-resistant Lyme arthritis is associated with response. It is anticipated that the functional character-HLA-DR4 and T-cell responses to the borrelial outer ization of T-cell epitopes in association with particular surface protein, OspA [53, 54] . Four immunodominant HLA molecules will offer therapeutic strategies for auto-T-cell epitopes of OspA have been defined in the immune, allergic and certain infectious diseases based DR*0401/hCD4/I-Ab°mouse model, as described on the regulation of cytokine profiles. above [55] .
Modification of disease The quality of the effector immune response
Murine disease models can be used to investigate the Defining T-cell epitopes in the context of diseaseeffect of single or multiple transgenic HLA molecules susceptible or disease-protective HLA molecules is a on disease expression. They also provide a method for prelude to understanding how particular peptide/HLA testing novel immunomodulatory therapies in vivo, partnerships might modify the nature of the immune accepting the usual caveats associated with the extraresponse and hence the natural history of disease. In autoimmune and allergic disease, aggressive T-cell polation of results from murine to human disease.
The first HLA transgenic disease model was the HLA-HLA transgenic murine lines have been established. These have already provided novel insights into the role B27 transgenic rat, which developed a spondyloarthropathy [61] . HLA-B27 transgenic mice also spontanof individual HLA molecules on T-cell epitope selection, the formation of the TCR repertoire and T-cell effector eously develop inflammatory arthritis in transgenic mice which lack b2-microglobulin [62] . This may reflect the function [28, 33, 55, 56 ] . The ultimate objectives of this research are to unravel the mechanisms underlying unusual stability and surface expression of HLA-B27 heavy chain in the absence of b2m [63] .
HLA-associated disease susceptibility or resistance, and to provide a model system in which to assess the efficacy CIA occurs only in the presence of susceptible murine MHC haplotypes, such as H-2q [47] . In of immunotherapeutic strategies, prior to designing clinical trials. I-Ab°mice, which lack murine class II molecules, CIA can also be induced in the presence of transgenic HLA-DR4 (DRA1*0401/DRB1*0401) back-crossed
